If you are searching for the amur minerals share price on financial portals today, you might be confused to find that the old ticker symbol, AMC, is no longer trading. The company has undergone a dramatic corporate rebirth. Following the sale of its Russian mining assets, Amur Minerals transitioned into an AIM cash shell and completed a reverse takeover (RTO) of Extruded Pharmaceuticals in May 2024. Rebranded as CRISM Therapeutics Corporation, the successor stock now trades under the ticker CRTX, with the share price hovering around 10.50p as of late May 2026.

This article provides a comprehensive guide for legacy shareholders and prospective investors on what happened to the old mining company, how the share consolidation changed your portfolio, the current financial health of CRISM Therapeutics, and what to expect from the stock moving forward.

The Transition from Mining to Biotech: Why Amur Minerals Disappeared

Historically, Amur Minerals Corporation was an AIM-listed exploration and development company focused on base metals in the Russian Far East. Its crown jewel was the Kun-Manie nickel-copper sulphide project in the Amur Province, a massive deposit that held substantial promise during the global push for battery metals. However, the geopolitical events of 2022 and 2023 dramatically changed the operational landscape. West-led sanctions, coupled with massive capital restrictions, made it impossible for a London-listed junior miner to develop a capital-intensive project in the Russian Federation.

In response to these existential challenges, the Amur board made the strategic decision to exit Russia entirely. In March 2023, the company finalized the sale of its wholly owned Russian subsidiary, AO Kun-Manie, for a gross consideration of $35 million. While this transaction successfully liquidated the company's main asset, it fundamentally changed the nature of the business. To reward patient retail investors, the company promptly distributed a special dividend of 1.8 pence per share from the sale proceeds within 90 days of completion.

Under Rule 15 of the AIM Rules for Companies, the disposal of its sole operating asset reclassified Amur Minerals as an "AIM cash shell". According to AIM guidelines, a cash shell is given exactly six months to complete an acquisition that constitutes a reverse takeover (RTO) under Rule 14, or to be readmitted as an investing company. If it fails to do so, its shares are suspended from trading on the London Stock Exchange.

Amur’s board, led by former CEO Robin Young, diligently searched for a suitable RTO target. They evaluated over 17 distinct opportunities globally across sectors such as potash, silica, copper, nickel, gold, and lithium. Geographically, these prospects spanned Canada, the US, Scandinavia, Brazil, Chile, and Australia. Unfortunately, none of these discussions bore fruit within the initial six-month window, resulting in the official suspension of AMC shares on September 7, 2023.

Facing the threat of total delisting under AIM Rule 41 (which occurs if a suspended company fails to complete an RTO within six months of suspension), the board expanded its search beyond the mining sector. On May 13, 2024, Amur announced that it had executed a sale and purchase agreement to acquire Extruded Pharmaceuticals Limited (EPL), a UK-based drug delivery technology company, for £5.5 million in shares. This successful pivot saved the company from permanent delisting and set the stage for its complete transformation into a clinical-stage biotechnology pioneer.

The 1:160 Share Consolidation: What Happened to Your AMC Shares?

One of the most frequent sources of confusion for investors tracking the amur minerals share price is the sudden and massive drop in the number of shares they held in their portfolios. When the reverse takeover of Extruded Pharmaceuticals was approved by shareholders on May 29, 2024, several key corporate restructurings took place simultaneously:

1. Corporate Name Change: Amur Minerals Corporation was renamed CRISM Therapeutics Corporation to reflect its new focus on medical treatments.
2. Ticker Symbol Change: The old ticker symbol "AMC" was retired, and the new ticker symbol "CRTX" was introduced on the London Stock Exchange's AIM market.
3. Board Shake-Up: The old minerals-focused board resigned, replaced by pharmaceutical industry experts including Dr. Nermeen Varawalla as independent non-executive chair and Andrew Webb as CEO.
4. Share Consolidation: The company implemented a 1-for-160 share consolidation.

Understanding the Share Consolidation Math

A share consolidation, commonly referred to as a reverse stock split, reduces the total number of outstanding shares while proportionally increasing the nominal value of each remaining share. This is a common practice during reverse takeovers of penny stocks to establish a more stable, institutionally acceptable trading price.

Before the suspension in September 2023, Amur Minerals shares were trading at a nominal value of roughly 0.09 pence (less than a tenth of a penny). To launch the newly merged CRISM Therapeutics on AIM with a liquid and respectable share price, the 1-for-160 consolidation ratio was executed.

Here is how the math worked for a typical retail investor's portfolio:

• Formula: Old Share Count / 160 = New Share Count
• Example A (Large Holding): If you owned 160,000 shares of AMC at the time of suspension, your holding was consolidated into exactly 1,000 shares of the new ticker CRTX.
• Example B (Small Holding): If you owned 1,600 shares of AMC, you were left with exactly 10 shares of CRTX.

What happened to fractional shares? If your old share count was not perfectly divisible by 160, you were left with a fractional entitlement. Under the terms of the consolidation, these fractional shares were aggregated and sold on the open market, with the net proceeds distributed to shareholders where broker administration rules permitted.

Because of this transition, many legacy investors who logged into their brokerage accounts in June 2024 were alarmed to see their AMC shares listed as suspended, deleted, or displaying a value of zero. In reality, the shares had simply migrated to CRTX. If you still see anomalies in your portfolio, you should contact your stockbroker or the company’s share registrar to ensure your holding has been correctly updated to CRTX.

Understanding CRISM Therapeutics (LON: CRTX): A Clinical-Stage Biotech Pioneer

For legacy investors, the risk profile of their investment has fundamentally shifted. You are no longer holding a speculative mining explorer hoping to strike nickel in Siberia. Instead, you are now invested in a clinical-stage biotechnology company fighting some of the most aggressive forms of cancer.

CRISM Therapeutics Corporation's business is centered around improving the clinical performance of cancer treatments for solid tumors through the localized and sustained delivery of chemotherapy drugs. Its proprietary platform technology is known as ChemoSeed.

The Science of ChemoSeed

Solid tumors, particularly high-grade gliomas such as glioblastomas (a highly aggressive, terminal form of brain cancer), present massive challenges to modern medicine. Standard systemic chemotherapies are administered intravenously or orally, meaning they circulate through the entire body. To treat brain cancer, these drugs must cross the blood-brain barrier (BBB) — a highly selective semipermeable border of cells that protects the brain from foreign substances.

Because the BBB prevents most chemotherapy drugs from entering the brain, systemic treatments must be administered at incredibly high, toxic doses to achieve even a minor therapeutic effect at the tumor site. This results in severe, debilitating side effects for the patient, such as severe nausea, immune suppression, and organ damage, while often failing to stop the tumor from regrowing.

CRISM's ChemoSeed technology circumvents the blood-brain barrier entirely through a localized delivery system. The process works as follows:

1. Surgical Resection: A neurosurgeon performs surgery to remove as much of the brain tumor as safely possible.
2. Direct Implantation: Immediately following resection, the surgeon implants tiny, biodegradable polymer "seeds" (ChemoSeeds) directly into the cavity and resection margins — the edges where remaining microscopic tumor cells are most likely to linger.
3. Sustained Release: Over the following weeks, the ChemoSeeds slowly degrade, releasing precise, therapeutic concentrations of chemotherapy drugs (such as irinotecan) directly into the surrounding tissue.

By delivering the drug locally, ChemoSeed achieves maximum therapeutic concentrations directly at the tumor site while minimizing systemic exposure, protecting the rest of the patient's body from the toxic side effects of chemotherapy.

The Clinical Pipeline

CRISM’s primary focus is advancing its clinical pipeline to bring ChemoSeed to market. The company’s active programs include:

• Irinotecan-ChemoSeed (Glioblastoma): This is the company's lead product candidate, currently advancing into a Phase 2 open-label clinical trial. It is designed to target aggressive brain tumors post-surgery to prevent rapid regrowth.
• Docetaxel-ChemoSeed (Prostate Cancer): This program is in preclinical development, aiming to deliver localized treatment for solid prostate tumors to avoid the side effects of systemic hormone and chemotherapy treatments.

CRISM Therapeutics (LON: CRTX) Share Price & Financial Health in 2026

For investors monitoring the successor to the amur minerals share price, the stock's current performance reflects its status as an early-stage biopharmaceutical play. Trading under the ticker CRTX on the London Stock Exchange's AIM market, the stock has experienced significant volatility.

Share Price and Market Capitalization

As of late May 2026, the CRTX share price is trading around 10.50 pence.

Over the past 52 weeks, the stock has traded within a highly volatile range, hitting a low of 8.00 pence and reaching a high of 25.00 pence. With approximately 51.74 million ordinary shares in issue, CRISM Therapeutics has a market capitalization of roughly £5.43 million, classifying it as a micro-cap biotechnology stock.

Financial Metrics and Risk Profile

When evaluating CRTX, investors must understand the unique financial dynamics of the clinical-stage biotech sector:

• Minimal Revenues: For the fiscal year ending December 2024, CRISM reported revenues of just £25,000, derived primarily from specialized formulation and consultancy services. The company does not yet have a commercialized drug on the market and therefore lacks consistent, product-driven revenue.
• Ongoing Net Losses: The company operates at a net loss (with a net loss of approximately £607,000 in 2024) as all capital is channeled directly into research and development, clinical trials, and manufacturing compliance. These losses are expected to continue or widen as Phase 2 clinical trials progress.
• Dilution Risk: To keep its clinical trials funded, CRISM must regularly raise capital through the issuance of new shares. This has led to substantial dilution for existing shareholders over the past year, with the total number of outstanding shares increasing significantly.
• Debt-Free Balance Sheet: On the positive side, CRISM maintains a debt-free balance sheet. This is a critical advantage for micro-cap biotech companies, as it eliminates the threat of debt defaults and ensures that newly raised capital is spent entirely on advancing its medical pipeline rather than servicing high-interest debt.

The Latest Catalysts: Recent Fundraising & Phase 2 Trial Progress (May 2026 Updates)

The biotechnology sector is driven entirely by regulatory milestones, clinical trial progress, and funding announcements. Fortunately, May 2026 has been an incredibly active and positive month for CRISM Therapeutics, providing several major catalysts for the stock:

Oversubscribed Retail Offer and Capital Raise

On May 26, 2026, CRISM announced a significant follow-on equity offering to raise £2.5 million via a private placing of new ordinary shares at an issue price of 10 pence per share (with attached warrants). To allow individual retail investors to participate on the same terms, the company launched a corresponding Retail Offer.

On May 28, 2026, CRISM officially announced the results of the Retail Offer. The offer was heavily oversubscribed, demonstrating massive investor appetite for the company's oncology pipeline. In light of the high demand, the directors exercised their right to upsize the Retail Offer to £245,000 (via the issuance of 2,450,000 new ordinary shares).

This capital raise is a major milestone for the company. The proceeds will provide the necessary financial runway to:

1. Unlock additional non-dilutive government and institutional grant funding.
2. Fund and advance the Phase 2 open-label clinical trial of irinotecan-ChemoSeed for glioblastoma.
3. Support the ongoing preclinical development of docetaxel-ChemoSeed for prostate cancer.

The completion of the fundraising remains subject to formal shareholder approval, which will be voted on at a newly called General Meeting on June 15, 2026.

Regulatory and IP Successes

In addition to the successful fundraising, CRISM has secured major regulatory and intellectual property (IP) victories in early 2026:

• FDA Orphan Drug Designation (March 2026): The US Food and Drug Administration officially granted Orphan Drug Designation to irinotecan-ChemoSeed for the treatment of glioblastoma. This designation is highly coveted because it provides CRISM with seven years of market exclusivity in the United States upon FDA approval, significant tax credits for clinical trials, and a waiver of costly FDA application fees.
• Japanese Patent Grant (January 2026): The Japanese Patent Office granted a key patent protecting CRISM's localized drug delivery technology, solidifying the company's intellectual property moat in one of the world's largest pharmaceutical markets.

Frequently Asked Questions (FAQ)

Is Amur Minerals still trading?

No, Amur Minerals Corporation is no longer trading under its old name or its former ticker symbol "AMC". Following a reverse takeover of Extruded Pharmaceuticals in May 2024, the company was renamed CRISM Therapeutics Corporation and now trades under the ticker symbol CRTX on the London Stock Exchange's AIM market.

How do I check the current Amur Minerals share price?

To find the current price of the successor company, you must search for CRISM Therapeutics Corporation or use the ticker symbol CRTX on your trading platform, financial news website, or portfolio tracker. As of late May 2026, the share price is trading around 10.50 pence.

Why did my number of shares drop so significantly?

As part of the corporate transition in May 2024, shareholders approved a 1-for-160 share consolidation. This means that for every 160 old Amur Minerals (AMC) shares you owned, you received exactly 1 new share of CRISM Therapeutics (CRTX). While your total number of shares decreased by a factor of 160, the nominal value of each share was multiplied by 160, keeping the total starting value of your holding identical at the moment of the split.

What is CRISM Therapeutics' lead product?

CRISM's lead clinical candidate is irinotecan-ChemoSeed, an implantable, biodegradable polymer seed designed to deliver chemotherapy drugs directly to the site of brain tumors (specifically glioblastomas) post-surgery. This technology bypasses the blood-brain barrier, maximizing treatment efficacy while drastically reducing systemic toxicity.

Is CRTX stock a good investment?

Investing in CRTX carries high risks and potentially high rewards. As a clinical-stage biotech micro-cap, the company faces significant clinical trial risks, regulatory hurdles, and potential share dilution due to future fundraising. However, its debt-free balance sheet, recent FDA Orphan Drug Designation, and highly successful May 2026 oversubscribed fundraising make it an intriguing option for high-risk investors interested in cutting-edge oncology treatments.

Conclusion

While the era of Amur Minerals as a Siberian mining explorer has officially come to an end, its corporate shell has birthed a promising medical technology company. For legacy shareholders tracking the amur minerals share price, the transition to CRISM Therapeutics (CRTX) represented a complete reset of their investment thesis.

With a current share price of approximately 10.50p, a debt-free balance sheet, and a recently upsized, oversubscribed fundraising round in late May 2026, CRISM is now fully capitalized to advance its Phase 2 clinical trials for brain cancer. Investors must closely watch the upcoming General Meeting on June 15, 2026, and subsequent Phase 2 trial updates, as these milestones will ultimately dictate the future trajectory of CRTX.